qualified persons in installation qualification, operational qualification, and standard operating procedure protocols.
Side Effects Profile in Humans of 11 C-(1)-PHNO, a Dopamine D 2/3 Agonist Ligand for PET TO THE EDITOR: 11 C-(1)-4-propyl-9-hydroxynaphthoxazine ((1)-PHNO) is a new PET ligand developed by our group. Binding assays show that (1)-PHNO displays high affinity and selectivity for the D 2 receptor (1). Recently, it has been noted that 11 C-(1)-PHNO has a preferential affinity and selectivity in vivo for the D 3 receptors (2). Because 11 C-(1)-PHNO is an agonist radiotracer for D 2 and D 3 , it is likely to produce pharmacologic effects, in contrast to antagonist radiotracers. We reviewed all 11 C-(1)-PHNO consecutive scans obtained in our PET center for side effects. Mass injected (mg), subjects' weight (kg), and dose (mg/kg) were included in the analysis. Side effects were recorded on the basis of the subjects' self-report either during or right after finalization of the scan. A physician was available at all times to confirm and treat any possible side effects. Side effects were coded as 0 (no effect), 1 (nausea), or 2 (vomiting), based on our early experience with 11 C-(1)-PHNO (3). Odds ratios (ORs) were calculated using logistic regression analyses to investigate the relationship between dose, mass, and effects.
The number of reviewed 11 C-(1)-PHNO scans totalled 486. Injected mass ranged from 0.85 to 5.56 mg, with a mean of 2.30 mg (SE, 0.024 mg). Injected doses ranged from 0.01 to 0.08 mg/kg, with a mean of 0.03 mg/kg (SE, 0.0004 mg/kg). No effect was present in 84.6% of the scans reviewed; nausea was present in 14.3%, and vomiting in 1.1%. Symptoms arose 3-5 min after the injection and subsided within 7-12 min in all cases. In none of the cases was any medical action required.
In a logistic regression model including all subjects, nausea was significantly predicted by dose (Wald 5 21.70, P , 0.001, OR 1.99) and mass (Wald 5 16.319, P , 0.001, OR 5 2.826), and vomiting was significantly predicted by dose (Wald 5 7.31, P , 0.007, OR 5 2.66) but not by mass injected (Wald 5 0.694, P 5 0.405, OR 5 1.810). When only drug-free volunteers were analyzed (n 5 209), no effect was present in 79.8% of the cases, nausea was present in 18.7%, and vomiting in 1.5%. In a logistic regression model including only drug-free volunteers, nausea was significantly predicted by dose (Wald 5 6.98, P , 0.008, OR 1.54) and mass (Wald 5 11.981, P 5 0.001, OR 5 2.843).
Vomiting was predicted at a trend level by dose (Wald 5 3.33, P , 0.06, OR 2) but not by mass (Wald 5 0.105, P 5 0.746, OR 5 1.303). When only antipsychotic-treated participants were analyzed (n 5 66), no effect was present in 97% of the cases, nausea was present in 3%, and no vomiting was present in any. In a logistic regression model including only these subjects, nausea was significantly predicted neither by dose (Wald 5 2.25, P , 0.13) nor by mass (Wald 5 0.000, P 5 0.99). In all cases, when an injected dose of 0.029 mg/kg or less was selected, there was no relationship between dose and nausea.
The side effects reported in this study are consistent with the expected agonism at the D 2 -and D 3 -receptor (4-7).
We conclude that doses of 11 C-(1)-PHNO of 0.029 mg/kg or less are highly unlikely to produce any side effects in humans and that 11 C-(1)-PHNO is a safe agonist radiotracer for PET in human studies of health and disease. (1) . The authors claimed that the pretest intravenous insulin injection in diabetic patients is a realistic approach. However, several issues deserve further exploration before this standardized insulin protocol can be incorporated into daily PET practice.
In clinical tumor imaging, hyperglycemia has a recognized adverse effect on the quality of 18 F-FDG PET images because of competitive inhibition of 18 F-FDG uptake by glucose. Although insulin can be used as a glycemia-reducing agent, arbitrary prescription of insulin before 18 F-FDG injection may exacerbate muscular 18 F-FDG uptake and compromise tumor uptake, thus curtailing image interpretability (2) . According to the study results of Roy et al., 18 F-FDG PET image quality was barely adequate in 75% of patients receiving insulin. This means every 1 of 4 scans must be repeated. Repeating a study is not a cost-benefit if the PET center does not have its own on-site cyclotron. Rescheduling is inconvenient to the patients and bothersome to the center staff. The set point to prescribe insulin in the study protocol of Roy et al. might account for their poor image quality. The Society of Nuclear Medicine recommends rescheduling the examination if the patient's blood glucose level is greater than 8.3-11.1 mmol/L (150-200 mg/dL) (3). The European Association of Nuclear Medicine also advises that an 18 F-FDG PET study should not be performed when the blood glucose level exceeds 11.1 mmol/L (4). If cancelling an examination or rescheduling an appointment is not feasible, we suggest the use of intravenous insulin at a blood glucose level of more than 11.1 mmol/L, instead of the 10.0 mmol/L stated by Roy et al. Additionally, we encourage hyperglycemic patients to have a temperate walk after insulin injection to reduce muscular uptake. In this way, the proportion of images of adequate quality would improve.
In their study, less favorable image quality was found with more glycemic reduction after insulin administration, and no significant correlation was observed between muscular uptake and parameters such as initial glycemia, total insulin dose, and number of insulin doses. Hence, the extent of glycemic reduction is not predictable and the chance of study failure is unavoidable. The implication is that we cannot select which hyperglycemic patient is suitable for insulin use. We also cannot apply the correct insulin dose to manage glycemic reduction before imaging. These phenomena can be explained by nonuniform insulin sensitivity among hyperglycemic patients. Therefore, Roy's standardized insulin protocol, an illogical practice such as sliding-scale insulin (5) , is a problematic recipe for glycemic control in hyperglycemic patients undergoing 18 F-FDG PET studies. Sliding-scale insulin is also associated with poorer glycemic control, a harmful rollercoaster effect between hyperglycemic and hypoglycemic episodes, and increased risks of hypoglycemia, as occurred in 6 patients (9.5%) in the study of Roy et al. Thus, their standardized insulin protocol might be a risky strategy.
To obtain a useful diagnostic image of 18 F-FDG PET, one should ensure that the patient has fasted overnight and has a blood glucose level of less than 8.3 mmol/L in the early morning on the day of the PET scan. A good method is to do a ''practice run'' by checking the patient's blood glucose levels for at least 3 d before the 18 F-FDG PET appointment (6) . If the morning blood glucose level is persistently higher than 8.3 mmol/L, the scheduler needs to recognize this problem well before the scan appointment and request that the diabetologist manage the glycemic status by basal and nutritional insulin therapy with a supplemental insulin regimen (7) . To avert the possibility of irreversibly unreadable images, hypoglycemia, and transcellularshift hypokalemia, before establishing specific guidelines for using insulin in hyperglycemic patients undergoing 18 F-FDG PET we should have the patients fast and we should not administer additional insulin.
